Company ranked 6th in 2017 and in Top 10 for Third Year Running
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 10, 2017--
Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 6th on Forbes magazine’s
2017 list of the World’s Most Innovative Companies. Incyte, a
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics, is advancing an
innovative and diverse portfolio of large and small molecules comprised
of 17 development candidates against 14 different molecular targets.
“It is an honor to be recognized as one of the World’s Most Innovative
Companies by Forbes year-after-year,” said Hervé Hoppenot,
Incyte’s Chief Executive Officer. “At Incyte, innovation is in our DNA.
We push ourselves every day to be at the forefront of advancing science
as we research and develop treatments that will positively impact the
lives of patients around the world.”
Forbes’ ranking is based on the companies’ “innovation premium,”
and only includes industries that are known to invest in innovation and
businesses that have at least seven years of financial data and a market
value greater than $10 billion.
To view the complete list, visit http://www.forbes.com/innovative-companies/list/.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical
company focused on the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte, please
visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170810005610/en/
Source: Incyte Corporation
Catalina Loveman, +1 302 498
Booth, DPhil, +1 302 498 5914